Mixed-lineage kinase inhibitors require the activation of Trk receptors to maintain long-term neuronal trophism and survival

J Pharmacol Exp Ther. 2005 Mar;312(3):1007-19. doi: 10.1124/jpet.104.077800. Epub 2004 Nov 3.

Abstract

Small-molecule mixed-lineage kinase (MLK) inhibitors, such as CEP-1347 [3,9-bis[(ethylthio)methyl]-(8R*,9S*,11S*)-(-)-9-hydroxy-9-methoxycarbonyl-8-methyl-2,3,9,10-tetrahydro-8,11-epoxy-1H,8H, 11H-2,7b,11a-triazadibenzo(a,g)cycloocta(cde)trinden-1-one] and CEP-11004 [3,9-bis-[(isopropylthio)methyl]-(8R*,9S*,11S*)-(-)-9-hydroxy-9-methoxycarbonyl-8-methyl-2,3,9,10-tetrahydro-8,11-epoxy-1H,8H,11H-2,7b,11a-triazadibenzo(a,g)cycloocta(cde)trinden-1-one], prevent c-Jun NH(2)-terminal kinase (JNK) pathway activation as well as the consequent neuronal cell death in many cell culture and animal models. In the cell culture model of nerve growth factor (NGF)-deprived sympathetic neurons, we find that CEP-11004 induced a approximately 3-fold increase in the mRNA and protein levels of TrkA, the NGF receptor. This resulted in ligand-independent activation of the TrkA receptor and the downstream phosphatidylinositol 3-kinase (PI3-kinase) pathway. Addition of the Trk inhibitor K252a [(8R*,9S*,11S*)-(-)-9-hydroxy-9-methoxycarbonyl-8-methyl-2,3,9,10-tetrahydro-8,11-epoxy-1H,8H,11H-2,7b,11a-triazadibenzo(a,g)cycloocta(cde)-trinden-1-one] or the PI3-kinase inhibitor LY294002 [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] significantly decreased the protein synthesis rates, mitochondrial function, and neuronal survival maintained by CEP-11004. In contrast to sympathetic neurons, MLK inhibitors maintain only short-term survival of potassium- and serum-deprived rat cerebellar granule neurons (CGNs), despite continuous inhibition of the JNK pathway. We found that similar to sympathetic neurons, CEP-11004 increased the levels of the Trk receptor expressed in CGNs, TrkB. However, CGNs required the addition of the exogenous ligand brain-derived neurotrophic factor (BDNF) to activate the PI3-kinase pathway and to maintain long-term survival. BDNF activated TrkB, but caused rapid down-regulation of activated receptors and maintained only minimal survival. Therefore, increase in TrkB levels by CEP-11004 mediated a synergism with BDNF resulting in long-term survival in response to the combined treatment of CEP-11004 and BDNF. Taken together, our studies suggest that in addition to the direct inhibition of the JNK pathway, the indirect activation of the PI3-kinase pathway via Trk activation is important for MLK inhibitor-mediated neuronal survival and trophism.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Brain-Derived Neurotrophic Factor / pharmacology
  • Carbazoles / pharmacology*
  • Cell Survival / drug effects
  • Enzyme Inhibitors / pharmacology*
  • Indoles / pharmacology*
  • JNK Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • MAP Kinase Kinase Kinases / antagonists & inhibitors*
  • Nerve Growth Factor / pharmacology
  • Neurons / cytology
  • Neurons / drug effects*
  • Phosphatidylinositol 3-Kinases / physiology
  • RNA, Messenger / analysis
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, trkA / genetics
  • Receptor, trkA / physiology*
  • Receptor, trkB / physiology

Substances

  • Brain-Derived Neurotrophic Factor
  • CEP-11004
  • Carbazoles
  • Enzyme Inhibitors
  • Indoles
  • RNA, Messenger
  • 3,9-bis((ethylthio)methyl)-K-252a
  • Nerve Growth Factor
  • Phosphatidylinositol 3-Kinases
  • Receptor, trkA
  • Receptor, trkB
  • JNK Mitogen-Activated Protein Kinases
  • MAP Kinase Kinase Kinases